Date Title Document
Valeant Pharmaceuticals To Present At Industry Conferences Date 12/20/13 Title Valeant Pharmaceuticals To Present At Industry Conferences Download PDF
Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash Date 12/16/13 Title Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash Download PDF
Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance Date 12/13/13 Title Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance Download PDF
Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Date 12/02/13 Title Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Download PDF
Valeant Pharmaceuticals Announces New Management Appointment Date 11/25/13 Title Valeant Pharmaceuticals Announces New Management Appointment Download PDF
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Date 11/15/13 Title Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1% Date 11/15/13 Title Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1% Download PDF
Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Date 11/15/13 Title Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Download PDF
Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Date 11/15/13 Title Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results Date 10/31/13 Title Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results Download PDF
Valeant Pharmaceuticals Announces Settlement Agreement With Anacor Date 10/28/13 Title Valeant Pharmaceuticals Announces Settlement Agreement With Anacor Download PDF
Valeant Pharmaceuticals Announces Award In Anacor Dispute Date 10/18/13 Title Valeant Pharmaceuticals Announces Award In Anacor Dispute Download PDF
Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013 Date 10/08/13 Title Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013 Download PDF
Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada Date 10/03/13 Title Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada Download PDF
Valeant Pharmaceuticals' Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens Date 10/03/13 Title Valeant Pharmaceuticals' Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens Download PDF
Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence Date 10/02/13 Title Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence Download PDF
Valeant Pharmaceuticals Announces Continuance Date 08/09/13 Title Valeant Pharmaceuticals Announces Continuance Download PDF
Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results Date 08/07/13 Title Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb Date 08/06/13 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb Download PDF
Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013 Date 07/15/13 Title Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013 Download PDF
Medicis Announces Five-Year Aesthetic Collaboration with Mentor Date 07/02/13 Title Medicis Announces Five-Year Aesthetic Collaboration with Mentor Download PDF
Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Date 06/27/13 Title Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares Date 06/24/13 Title Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares Download PDF
Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option Date 06/20/13 Title Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option Download PDF
Valeant Pharmaceuticals Prices Public Offering Of Common Shares Date 06/18/13 Title Valeant Pharmaceuticals Prices Public Offering Of Common Shares Download PDF
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Date 06/18/13 Title Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Announces Public Offering Of Common Shares Date 06/17/13 Title Valeant Pharmaceuticals Announces Public Offering Of Common Shares Download PDF
Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus Date 06/07/13 Title Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus Download PDF
Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole Date 05/28/13 Title Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole Download PDF
Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion Date 05/27/13 Title Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion Download PDF
Valeant Pharmaceuticals Announces 2013 Annual Meeting Results Date 05/21/13 Title Valeant Pharmaceuticals Announces 2013 Annual Meeting Results Download PDF
Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference Date 05/20/13 Title Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference Download PDF
Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors Date 05/15/13 Title Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors Download PDF
Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders Date 05/13/13 Title Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal Date 05/10/13 Title Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal Download PDF
Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results Date 05/02/13 Title Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results Download PDF
Valeant Pharmaceuticals Provides Efinconazole Update Date 05/02/13 Title Valeant Pharmaceuticals Provides Efinconazole Update Download PDF
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel Date 05/01/13 Title Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc. Date 04/25/13 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc. Date 04/24/13 Title Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. Date 04/23/13 Title Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc. Date 04/22/13 Title Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013 Date 04/16/13 Title Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013 Download PDF
Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® Date 04/10/13 Title Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® Download PDF
Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape Date 04/05/13 Title Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape Download PDF
Valeant Pharmaceuticals Provides Update to Recent Event Date 04/04/13 Title Valeant Pharmaceuticals Provides Update to Recent Event Download PDF
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash Date 04/03/13 Title Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash Download PDF
Valeant Pharmaceuticals Announces Private Exchange Offer Date 03/29/13 Title Valeant Pharmaceuticals Announces Private Exchange Offer Download PDF
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash Date 03/20/13 Title Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash Download PDF
Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results Date 02/28/13 Title Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results Download PDF
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc. Date 02/21/13 Title Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc. Download PDF
Valeant Completes Acquisition Of Natur Produkt In Russia Date 02/01/13 Title Valeant Completes Acquisition Of Natur Produkt In Russia Download PDF
Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013 Date 01/31/13 Title Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013 Download PDF
Valeant Pharmaceuticals Announces New Management Appointment Date 01/03/13 Title Valeant Pharmaceuticals Announces New Management Appointment Download PDF
Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference Date 01/02/13 Title Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference Download PDF
Annual Report

2015 Annual Report

The right products
The right philosophy.
record organic growth.

View All